Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 12/20 | 0.50 |
| ▸ | CTSK | P43235 | 11/20 | 0.50 |
| ▸ | CTSL | P07711 | 2/20 | 0.48 |
| ▸ | CTSB | P07858 | 2/20 | 0.48 |
| ▸ | BMP1 | P13497 | 2/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | PPARA | Q07869 | 2/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7406870 | 0.88 | MMP3 (0.50) | CTSSCTSKCTSLCTSBCA1 | |
| SCHEMBL7406872 | 0.88 | MMP3 (0.50) | CTSSCTSKCTSLCTSBCA1 | |
| SCHEMBL8747641 | 0.87 | CTSK (0.52) | CTSSCTSKCTSLCTSBBMP1 | |
| SCHEMBL11166014 | 0.87 | CTSK (0.52) | CTSSCTSKCTSLCTSBBMP1 | |
| SCHEMBL30797986 | 0.85 | CTSS (0.49) | CTSSCTSKCTSLCTSBPPARA | |
| SCHEMBL13159728 | 0.85 | CTSS (0.46) | CTSSCTSKCTSLCTSBCA1 | |
| SCHEMBL13627772 | 0.85 | CTSK (0.46) | CTSSCTSKCTSLCTSBCA1 | |
| SCHEMBL30797870 | 0.85 | CTSS (0.49) | CTSSCTSKCTSLCTSBPPARA | |
| SCHEMBL1486220 | 0.84 | CTSS (0.50) | CTSSCTSKCTSLCTSBCA1 | |
| SCHEMBL688341 | 0.84 | CTSS (0.50) | CTSSCTSKCTSLCTSBCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2049104-B1 | PYRROLIDINONE ANILINES AS PROGESTERONE RECEPTOR MODULATORS | GLAXOSMITHKLINE LLC (US) | 2012-09-19 | — | — | EP | disclosed |
| US-7816395-B2 | Pyrrolidinone anilines as progesterone receptor modulators | GLAXOSMITHKLINE LLC (US) | 2010-10-19 | — | — | US | disclosed |
| US-20100210706-A1 | PYRROLIDINONE ANILINES AS PROGESTERONE RECEPTOR MODULATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2010-08-19 | — | — | US | disclosed |
| EP-2049104-A2 | PYRROLIDINONE ANILINES AS PROGESTERONE RECEPTOR MODULATORS | SmithKline Beecham Corporation (US) | 2009-04-22 | — | — | EP | disclosed |
| WO-2008021796-A2 | PYRROLIDINONE ANILINES AS PROGESTERONE RECEPTOR MODULATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-02-21 | — | — | WO | disclosed |
| US-20080039517-A1 | PYRROLIDINONE ANILINES AS PROGESTERONE RECEPTOR MODULATORS | GLAXOSMITHKLINE LLC | 2008-02-14 | — | — | US | disclosed |
| EP-0527764-A1 | PHOSPHONOPEPTIDES WITH COLLAGENASE INHIBITING ACTIVITY | Beecham Group p.l.c. (GB) | 1993-02-24 | — | — | EP | disclosed |
| WO-1991015507-A1 | PHOSPHONOPEPTIDES WITH COLLAGENASE INHIBITING ACTIVITY | BEECHAM GROUP PLC (GB) | 1991-10-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039517-A1 | PYRROLIDINONE ANILINES AS PROGESTERONE RECEPTOR MODULATORS | PGR, PGRMC2, PGRMC1 | CTSS 4230/4885CTSK 4301/4885CTSL 4194/4885 |
| US-20100210706-A1 | PYRROLIDINONE ANILINES AS PROGESTERONE RECEPTOR MODULATORS | PGR, PGRMC2, PGRMC1 | CTSS 4230/4885CTSK 4301/4885CTSL 4194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.